DDX11 and hepatocellular carcinoma: Detailed analysis revealed that both in early TNM stages (stage I and II) and late stages (stage III and IV)), patients with high DDX11 expression had shorter OS and disease-free survival (DFS) durations than patients with low DDX11 expression in TCGA-LIHC cohorts, which indicated that DDX11 expression level might be indicative of the prognosis of HCC patients at various clinical stages (Fig. 3g–j).